Drug Resistance in Colorectal Cancer: Molecular Mechanisms and Therapeutic Strategies, Volume Eight, summarizes the molecular mechanisms of drug resistance in colorectal cancer, along with the most up-to-date therapeutic strategies available. The book discusses reasons why colorectal tumors become refractory during the progression of the disease, but also explains how drug resistance occurs during chemotherapy. In addition, users will find the current therapeutic strategies used by clinicians in their practice in treating colorectal cancer. The combination of conventional anticancer drugs with chemotherapy-sensitizing agents plays a pivotal role in improving the outcome of colorectal cancer patients, in particular those with drug-resistant cancer cells.
From a clinical point-of-view, the content of this book provides clinicians with updated therapeutic strategies for a better choice of drugs for drug-resistant colorectal cancer patients. It will be a valuable source for cancer researchers, oncologists and several members of biomedical field who are dedicated to better treat patients with colorectal cancer.
Please Note: This is an On Demand product, delivery may take up to 11 working days after payment has been received.
1. Drug resistence in colorectal cancer: General aspects
2. Drug transporters in the development of multidrug resistance in colorectal cancer
3. Role pf colorectal cancer stem cells in resistance to apoptosis and treatment in colorectal cancer
4. Serrated lesions and stem cells on drug resistance and colon cancer
5. Development of novel microRNA-based therapeutics platform for colorectal cancer
6. Chemo-sensitizing agents for naturalorigin for colorectal cancer: Pharmacokinetics approaches
7. Induction of programmed necrosis by phytochemicals in colorectal cancer
8. Predictive biomarkers of drug resistance in colorectal cancer Recent updates
9. Raclb: An emerging therapeutic target for chemoresistance in colorectal cancer
10. Nanotechnology-based targeted drug delivery systems and drug resistance in colorectal cancer
11. Targeting colorectal cancer via nanodrug delivery systems
He has served on leading journals in the fields of gastroenterology and pharmacology and as editor of seven books related to inflammation and cancer. He has held numerous senior positions, including the Chair of Pharmacology at Hong Kong University, Chairman and Professor of Pharmacology at the Chinese University of Hong Kong (CUHK), and Research Professor and Associate Director of the School of Biomedical Sciences in the Faculty of Medicine, CUHK. Professionally, he was the President (2006-2010) and Chair of the Presidential Council (2012-2015) of the Gastrointestinal Pharmacology Section of the International Union of Basic and Clinical Pharmacology, and council member of a number of professional bodies in ulcer research and gastrointestinal pharmacology. Tao Hu Senior Fellow, University of Washington, USA. Dr. Hu obtained his Ph.D. from The Chinese University of Hong Kong, his research interests focus on the development of novel chemotherapeutic agents for the treatment of colorectal cancer, in particular the drug-resistant colorectal cancer. He published more than 20 peer-reviewed papers in this field and served as editorial board member or reviewer for more than 10 international journals in the field of pharmacology and gastroenterology.